Navigation Links
One shot of gene therapy spreads through brain in animal study
Date:10/8/2007

By targeting a site in a mouse brain well connected to other areas, researchers successfully delivered a beneficial gene to the entire brainafter one injection of gene therapy. If these results in animals can be realized in people, researchers may have a potential method for gene therapy to treat a host of rare but devastating congenital human neurological disorders, such as Tay-Sachs disease.

Researchers from The Childrens Hospital of Philadelphia and the University of Pennsylvania reported their findings in the September 12 issue of the Journal of Neuroscience.

After a single injection, this technique succeeded in correcting diseased areas throughout the brain, said study leader John H. Wolfe, V.M.D., Ph.D., a neurology researcher at The Childrens Hospital of Philadelphia and a professor of pathology and medical genetics at the Penn School of Veterinary Medicine. This may represent a new strategy for treating genetic diseases of the central nervous system.

Wolfe and Penn graduate student Cassia N. Cearley performed the study in mice specially bred to have the neurogenetic disease mucopolysaccharidosis type VII (MPS VII). In people, MPS VII, also called Sly syndrome, is a rare, multisystem disease causing mental retardation and death in childhood or early adulthood.

Sly syndrome is one of a class of some 60 disorders called lysosomal storage diseases that collectively cause disabilities in about one in 5,000 births. Those diseases account for a significant share of childhood mental retardation and severe, often fatal, disabilities. In each of the lysosomal storage diseases, a defect in a specific gene disrupts the production of an enzyme that cleans up waste products from cells. Cellular debris builds up within cell storage sites called lysosomes, and the waste deposits interfere with basic cell functions. Other examples of lysosomal storage diseases are Tay-Sachs disease, Hunter disease and Pompe disease.

In some types of the lysosomal storage disorder Gaucher disease, physicians can supply the missing enzyme to patients and successfully relieve disease symptoms. However, for Sly syndrome and most other lysosomal storage diseases, enzyme replacement, when available, is not very effective in treating the brain component of the disease. Enzymes delivered to the circulation do not cross the blood-brain barrier very well, said Dr. Wolfe.

Therefore, some strategies for treating these diseases have focused on gene therapydelivering DNA sequences that can enter cells and produce the needed enzyme. Researchers have also sought to deliver gene therapy directly to the brain rather than to the bloodstream, but there are practical limitations to making multiple injections into a childs brain.

In the current study, Wolfe targeted a particular region of the mouse brain called the ventral tegmental area (VTA), which has numerous connections with the rest of the brain. He used a neutralized virus called adeno-associated virus (AAV) as a vectorthe delivery vehicle for the gene that carries coded instructions to produce the desired enzyme.

We found that one subtype of AAV was particularly effective for transporting the gene, said Wolfe. The neural pathways carried the virus throughout the brain, where the gene produced the enzyme. The enzyme then cleaned up the storage lesions to the point that these storage lesions were indistinguishable from those found in the brains of normal mice. One advantage of lysosomal enzymes, said Wolfe, is that cells receiving the delivered gene secrete beneficial enzymes to neighboring cells, creating a sphere of correction.

The level of correction resulting from a single injection was unprecedented, said Wolfe, but he cautioned that direct human treatments might be years away. In future studies, he will investigate whether this technique is effective in animals larger than mice. Such results might conceivably resemble a 2005 study in which Wolfe used gene therapy to successfully treat another lysosomal storage disease, called alpha-mannosidosis, in cats. In that study, a treated cat showed dramatic improvement in walking, compared to an untreated cat with the disease.

If the animal results can be successfully extrapolated to humans, Wolfe estimates that 2 milliliters of injected gene therapy might treat a one-year-old child. That amount might be administered with a reasonably limited number of injections, he added, although a great deal of work would be needed to reach that goal.

Grants from the National Institutes of Health supported this research.


'/>"/>
Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Acupuncture May Help Chemotherapy Side Effects
4. Antioxidants protect health tissue in people undergoing radiation therapy.
5. Distraction therapy found very effective in postoperative patients
6. Gene Therapy shows promise in treating Hemophilia
7. "Make AIDS Therapy affordable" - Physicians demand
8. Acupuncture superseeds massage therapy for short term relief of pain
9. Hormone replacement Therapy a headache
10. Simple Therapy
11. Ovarian cancer in relationship with Hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been ... presented by the American Institute of Architects and the Academy of Architecture for Health. ... Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC ... Stong is double board certified and the only facial plastic surgeon in Atlanta to ... Non-surgical therapies such as stem cells can be used to provide stabilization to hair ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week 2016, ... the United States to thank a nurse who's made a difference in their life. ... the American Red Cross of San Diego/Imperial Counties (up to $10,000) every time someone ...
(Date:5/5/2016)... Boston, MA (PRWEB) , ... May 05, 2016 , ... ... stress becomes a constant presence, it can weaken the immune system and increase inflammation, ... Ami B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts ...
(Date:5/5/2016)... PLAINSBORO, N.J. (PRWEB) , ... May 05, 2016 , ... ... on patients with cancer, today announced a new collaboration with Imerman Angels ... of cancer anywhere in the world. , “Imerman Angels provides an emotional lifeline to ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 Research ... PET Imaging in Top 5 EU Markets"  report to their ... This report provides information on the current Positron Emission Tomography ... European Markets (T5 EU), which includes France ... , Spain and the ...
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... Yissum Research Development Company of the ... had signed an exclusive world-wide licensing and research agreement ... degradation and immunomodulatory drugs for cancer and immune dysfunction, ... first-in-class therapy for hematologic and solid malignancies. Financial terms ... novel technology was developed by Yinon Ben-Neriah , ...
Breaking Medicine Technology: